• BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics.
• The deal marks a major change for Amicus Therapeutics and its commercial portfolio.
• The transaction is viewed as a material event for shareholders and the wider biotechnology sector.

For investors watching Amicus Therapeutics, NasdaqGM:FOLD, the new acquisition agreement with BioMarin comes at a time when the stock is trading at $14.34. Over the past year, the share price return of 58.8% and 34.5% over five years reflects the level of attention the company has attracted in rare disease therapeutics.

This deal may change how Amicus Therapeutics operates, including its product lineup and its long term priorities under BioMarin's ownership. If you hold or track NasdaqGM:FOLD, it is a development to watch as details around integration, timelines, and any changes to the combined business become clearer.

Stay updated on the most important news stories for Amicus Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amicus Therapeutics.

The BioMarin deal effectively hands Amicus a new parent with scale in rare disease treatments, while giving BioMarin access to a commercial portfolio that already has global reach. Galafold and Pombiliti + Opfolda are central to that, and BioMarin plans to add them, along with the late stage DMX 200 pipeline asset, to its own lineup if the transaction closes as indicated in Q2 2026. For you as an investor, that means the focus shifts from Amicus as a standalone rare disease specialist to Amicus as part of a larger group that already operates multiple commercial therapies in similar niches to companies such as Vertex Pharmaceuticals, Sarepta Therapeutics and Alexion under AstraZeneca.

How This Fits Into The Amicus Therapeutics Narrative

• The planned acquisition aligns with the existing narrative around broader patient reach and international expansion, as BioMarin’s global infrastructure could support wider access for Galafold, Pombiliti + Opfolda and any future products such as DMX 200.
• The earlier narrative assumed Amicus would pursue its own path to profitability and operating leverage. The transaction introduces integration factors and capital allocation decisions that may differ from those standalone expectations.
• The narrative focuses largely on product uptake and pipeline execution. Acquisition-specific items such as deal terms, regulatory approvals and potential changes in portfolio priorities under BioMarin are not fully reflected.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Amicus Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The transaction still depends on regulatory and shareholder approvals, and any delays or conditions could affect timing and visibility for investors holding NasdaqGM:FOLD.
• ⚠️ Integration into a larger organization can result in shifts in pipeline priorities, which may influence how resources are allocated to assets like DMX 200 relative to other BioMarin programs.
• 🎁 If completed as announced, the US$4.8b deal value and planned addition of Galafold, Pombiliti + Opfolda and DMX 200 to BioMarin’s portfolio indicate clear commercial intent around Amicus’s core assets.
• 🎁 Amicus reported a full year 2025 net loss of US$27.11 million, narrower than the prior year, and Q4 2025 adjusted earnings of US$0.10 per share with net income of US$1.7 million, which shows the business entering the deal with improving profitability metrics.

What To Watch Going Forward

From here, it is worth tracking how quickly regulatory reviews progress and how firmly the Q2 2026 closing timeline holds. The planned shareholder meeting scheduled for March 3, 2026 is a key date, as it should clarify investor support for the transaction and any conditions attached. You may also want to watch BioMarin’s commentary on where Galafold, Pombiliti + Opfolda and DMX 200 fit alongside its existing rare disease products, as that will shape product specific priorities. Finally, quarterly updates from Amicus before closing will still matter, particularly around net product revenue trends and any changes to expectations that could influence the combined company’s starting point.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Amicus Therapeutics, head to the community page for Amicus Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.